HUP9904177A2 - Humán mellékpajzsmirigyhormon-szerű protein elleni ellenanyagok - Google Patents

Humán mellékpajzsmirigyhormon-szerű protein elleni ellenanyagok

Info

Publication number
HUP9904177A2
HUP9904177A2 HU9904177A HUP9904177A HUP9904177A2 HU P9904177 A2 HUP9904177 A2 HU P9904177A2 HU 9904177 A HU9904177 A HU 9904177A HU P9904177 A HUP9904177 A HU P9904177A HU P9904177 A2 HUP9904177 A2 HU P9904177A2
Authority
HU
Hungary
Prior art keywords
antibodies
antibody against
against human
related peptides
human parathormone
Prior art date
Application number
HU9904177A
Other languages
English (en)
Inventor
Kou Sato
Yuji Wakahara
Naohiro Yabuta
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HUP9904177A2 publication Critical patent/HUP9904177A2/hu
Publication of HUP9904177A3 publication Critical patent/HUP9904177A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát hűmán mellékpajzsmirigy-hőrmőnszerű prőtein elleniellenanyagők képezik, tővábbá az ellenanyagőkat kódőló DNS-ek, a DNS-eket tartalmazó rekőmbináns vektőrők, a rekőmbináns vektőrraltraszfőrmállt transzfőrmánsők, eljárásők az ellenanyagyőkelőállítására, valamint az ellenanyagők alkalmazása. A találmányszerinti ellenanyagők alkalmasak hiperkalcémia, hiperfőszfatémia éshasőnló rendellenességek kezelésére. ŕ
HU9904177A 1996-09-26 1997-09-24 Antibody against human parathormone related peptides HUP9904177A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25519696 1996-09-26
JP21416897 1997-07-24
PCT/JP1997/003382 WO1998013388A1 (fr) 1996-09-26 1997-09-24 Anticorps contre les peptides lies a la parathormone humaine

Publications (2)

Publication Number Publication Date
HUP9904177A2 true HUP9904177A2 (hu) 2000-03-28
HUP9904177A3 HUP9904177A3 (en) 2001-10-29

Family

ID=26520176

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904177A HUP9904177A3 (en) 1996-09-26 1997-09-24 Antibody against human parathormone related peptides

Country Status (17)

Country Link
US (3) US6903194B1 (hu)
EP (1) EP0962467A4 (hu)
KR (1) KR100847441B1 (hu)
CN (1) CN100335501C (hu)
AU (1) AU744146B2 (hu)
BR (1) BR9713294A (hu)
CA (1) CA2266332C (hu)
CZ (1) CZ106299A3 (hu)
HK (1) HK1096974A1 (hu)
HU (1) HUP9904177A3 (hu)
IL (1) IL129164A (hu)
NO (1) NO991449L (hu)
RU (1) RU2198220C2 (hu)
SK (1) SK40599A3 (hu)
TR (1) TR199900666T2 (hu)
TW (1) TW509697B (hu)
WO (1) WO1998013388A1 (hu)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
CA2332128A1 (en) * 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis
CA2372585A1 (en) * 1999-05-10 2000-11-16 Chugai Seiyaku Kabushiki Kaisha Method of culturing cells
WO2001002011A1 (fr) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
HUP0202218A3 (en) * 1999-07-06 2005-01-28 Chugai Pharmaceutical Co Ltd Remedies for drug-resistant hypercalcemia
KR20030008205A (ko) 1999-10-01 2003-01-24 추가이 세이야쿠 가부시키가이샤 혈액응고 관련 질환의 예방 및 치료
EP1254666A4 (en) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
WO2001054725A1 (fr) * 2000-01-25 2001-08-02 Chugai Seiyaku Kabushiki Kaisha Remèdes et agents prophylactiques pour maladies dentaires
WO2001064249A1 (en) * 2000-02-28 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Tissue decomposition inhibitor
AU2001252618A1 (en) * 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
WO2002013860A1 (fr) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
EP1312378A4 (en) * 2000-08-16 2004-03-17 Chugai Pharmaceutical Co Ltd AGENTS FOR THE RELIEF OF SYMPTOMS CAUSED BY JOINT DISEASES
WO2002052005A1 (fr) 2000-12-22 2002-07-04 Kazusa Dna Research Institute Foundation Genes et proteines codees par ceux-ci
WO2002072615A1 (fr) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US8949082B2 (en) 2001-11-02 2015-02-03 Siemens Medical Solutions Usa, Inc. Healthcare information technology system for predicting or preventing readmissions
WO2003040990A2 (en) * 2001-11-02 2003-05-15 Siemens Medical Solutions Usa, Inc. Patient data mining for quality adherence
US7457731B2 (en) 2001-12-14 2008-11-25 Siemens Medical Solutions Usa, Inc. Early detection of disease outbreak using electronic patient data to reduce public health threat from bio-terrorism
JP4364645B2 (ja) 2002-02-14 2009-11-18 中外製薬株式会社 抗体含有溶液製剤
FR2841788B1 (fr) * 2002-07-05 2006-01-27 Univ Pasteur Utilisation d'antagonistes de la pthrp pour traiter le carcinome a cellules renales
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
US7680086B2 (en) * 2002-09-09 2010-03-16 Siemens Canada Limited Wireless local area network with clients having extended freedom of movement
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
EP1565478B1 (en) * 2002-11-12 2017-08-02 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7794711B2 (en) * 2002-11-18 2010-09-14 Chugai Seiyaku Kabushiki Kaisha Agent for treating chondroma and chondrosarcoma
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
DK1745075T3 (da) 2004-04-21 2013-06-24 Brigham & Womens Hospital Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
CN111925445A (zh) 2004-07-09 2020-11-13 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
US20080275731A1 (en) * 2005-05-18 2008-11-06 Rao R Bharat Patient data mining improvements
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP3348639A3 (en) 2005-06-10 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Sc(fv)2 site-directed mutant
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
EP1896047A4 (en) * 2005-06-17 2009-07-22 Biogen Idec Inc ANTI-GFRALPHA3 ANTIBODIES
JPWO2007046439A1 (ja) 2005-10-18 2009-04-23 独立行政法人農業生物資源研究所 抗体を産生するトランスジェニックカイコとその製造方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5311303B2 (ja) 2006-04-25 2013-10-09 国立大学法人 東京大学 アルツハイマー病および癌の治療薬
RU2009100930A (ru) 2006-06-14 2010-07-20 Чугаи Сейяку Кабусики Кайся (Jp) Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
AU2007311957A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CA2666809A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
WO2008093688A1 (ja) 2007-01-30 2008-08-07 Forerunner Pharma Research Co., Ltd. キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
US7897139B2 (en) * 2007-08-17 2011-03-01 Biochrom Pharma, Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
US8501929B2 (en) 2007-08-17 2013-08-06 Biochrom Pharma Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
DK2315747T3 (en) 2008-07-21 2018-02-26 Brigham & Womens Hospital Inc Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides
JP5593488B2 (ja) 2008-11-17 2014-09-24 独立行政法人国立がん研究センター 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
EP2468771A4 (en) 2009-08-17 2013-06-05 Forerunner Pharma Res Co Ltd PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY TO HB-EGF AS AN ACTIVE SUBSTANCE
US8751495B2 (en) * 2009-09-29 2014-06-10 Siemens Medical Solutions Usa, Inc. Automated patient/document identification and categorization for medical data
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
US20110184761A1 (en) * 2010-01-25 2011-07-28 Siemens Medical Solutions Usa, Inc. Method and Apparatus for Estimating Patient Populations
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
EP3153583B1 (en) 2010-12-31 2021-10-20 BioAtla, Inc. Express humanization of antibodies
GB2502462B (en) 2011-01-10 2018-08-08 Univ Michigan Regents Stem cell factor inhibitor
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
JP6286757B2 (ja) 2012-04-23 2018-03-07 ジーンフロンティア株式会社 抗ヒトｃｄ６９抗体、及びその医薬用途
TWI606066B (zh) 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
US10565315B2 (en) 2012-09-28 2020-02-18 Cerner Innovation, Inc. Automated mapping of service codes in healthcare systems
US10318635B2 (en) 2012-09-28 2019-06-11 Cerner Innovation, Inc. Automated mapping of service codes in healthcare systems
US10403391B2 (en) 2012-09-28 2019-09-03 Cerner Health Services, Inc. Automated mapping of service codes in healthcare systems
CN108424453B (zh) 2012-11-09 2021-08-06 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
WO2015006554A1 (en) * 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10540448B2 (en) 2013-07-15 2020-01-21 Cerner Innovation, Inc. Gap in care determination using a generic repository for healthcare
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US20160304622A1 (en) 2013-10-15 2016-10-20 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
CA2935143C (en) 2013-12-27 2024-05-07 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
SG10201808565QA (en) 2014-03-31 2018-11-29 Debiopharm Int Sa Fgfr fusions
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
BR112018002432A2 (pt) 2015-09-18 2018-09-18 Chugai Pharmaceutical Co Ltd anticorpos de ligação à il-8 e usos dos mesmos
KR20180069839A (ko) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
US11332527B2 (en) 2017-10-12 2022-05-17 Keio University Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
CN112512480A (zh) 2018-05-21 2021-03-16 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
US11643458B2 (en) 2018-05-31 2023-05-09 Shionogi & Co., Ltd. Monoclonal antibody against Nav1.7
BR112021011431A2 (pt) 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
JPWO2022004760A1 (hu) 2020-06-30 2022-01-06
JPWO2023058723A1 (hu) 2021-10-08 2023-04-13
JP7457880B2 (ja) 2021-11-01 2024-03-28 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5001223A (en) 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
EP0293130A3 (en) 1987-05-26 1990-06-13 Merck & Co. Inc. Dimers of parathyroid hormone antagonists
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5217896A (en) 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
JPH02207099A (ja) 1989-02-07 1990-08-16 Tonen Corp ＰＴＨｒＰ関連ペプチド、その製造法及び用途
CA2035179C (en) 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
JPH04228089A (ja) 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
EP0539491A1 (en) 1990-07-13 1993-05-05 The Regents Of The University Of California PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9
DE4034612A1 (de) * 1990-10-31 1992-05-07 Huels Chemische Werke Ag Verfahren zur herstellung von methacryloxy- oder acryloxygruppen enthaltenden organosilanen
CA2107569C (en) 1991-04-05 2011-08-02 Gino V. Segre Parathyroid hormone receptor and dna encoding same
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
DE4137744C2 (de) * 1991-11-15 1996-10-31 Kuesters Eduard Maschf Verfahren zum Herstellen eines Schichtwerkstoffs unter Wiederverwendung von Kunststoffabfällen und eigensteifer, Kunstsoffabfälle enthaltender Schichtwerkstoff
WO1993013133A1 (en) * 1991-12-20 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa
US5993617A (en) * 1991-12-26 1999-11-30 Asahi Glass Company Ltd. Functional product
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3504697B2 (ja) 1993-09-30 2004-03-08 株式会社先端生命科学研究所 ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
JPH07316195A (ja) 1994-05-25 1995-12-05 Nippon Kayaku Co Ltd 新規なＰＴＨｒＰ関連ペプチド及びその用途
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
EP0813423B1 (en) * 1995-01-23 2002-07-03 Xenotech Incorporated Composition to inhibit osteolysis and metastasis
US5626845A (en) 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
DE69637104T2 (de) 1995-02-20 2008-01-31 Yukio Kato Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
ES2153564T3 (es) 1995-03-01 2001-03-01 Stryker Corp Regeneracion de la dentina inducida por un morfogeno.
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
US5660826A (en) 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
EP0871883A1 (en) 1995-07-20 1998-10-21 Icn Pharmaceuticals Compounds and methods related to parathyroid hormone-like protein
EP1166796A3 (en) 1996-02-01 2002-03-06 Chugai Seiyaku Kabushiki Kaisha Agents for preventing and treating thrombocytopenia
ATE360689T1 (de) 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
JP4228089B2 (ja) 1997-03-11 2009-02-25 株式会社ニコン 過電流検知機構およびそれを用いた電子閃光装置
JP4372240B2 (ja) 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
JP3791863B2 (ja) 1997-07-04 2006-06-28 株式会社フジタ 鉄筋コンクリート系建物の制震構造
JP4414494B2 (ja) 1998-02-03 2010-02-10 旭化成ファーマ株式会社 白血球減少症の予防剤および治療剤
ES2302374T3 (es) 1998-05-05 2008-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compuesto selectivo de receptores pth2.
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
CA2332128A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis

Also Published As

Publication number Publication date
NO991449D0 (no) 1999-03-25
EP0962467A4 (en) 2002-10-30
US7358355B2 (en) 2008-04-15
RU2198220C2 (ru) 2003-02-10
CA2266332A1 (en) 1998-04-02
TW509697B (en) 2002-11-11
NO991449L (no) 1999-05-25
US6903194B1 (en) 2005-06-07
SK40599A3 (en) 2000-06-12
US7842790B2 (en) 2010-11-30
KR20060006981A (ko) 2006-01-20
IL129164A0 (en) 2000-02-17
AU4397297A (en) 1998-04-17
BR9713294A (pt) 2000-10-17
CA2266332C (en) 2012-01-03
KR100847441B1 (ko) 2008-07-21
HK1096974A1 (en) 2007-06-15
HUP9904177A3 (en) 2001-10-29
CN100335501C (zh) 2007-09-05
CZ106299A3 (cs) 1999-08-11
AU744146B2 (en) 2002-02-14
IL129164A (en) 2007-05-15
TR199900666T2 (xx) 1999-06-21
EP0962467A1 (en) 1999-12-08
WO1998013388A1 (fr) 1998-04-02
US20050136057A1 (en) 2005-06-23
US20080095772A1 (en) 2008-04-24
CN1237983A (zh) 1999-12-08

Similar Documents

Publication Publication Date Title
HUP9904177A2 (hu) Humán mellékpajzsmirigyhormon-szerű protein elleni ellenanyagok
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
HK1007744A1 (en) Urethane-protected amino acid-n-carboxyanhydrides
EP1619202A3 (en) immunotherapeutic methods using epitopes of wt-1 and gata-1
DE3856560D1 (de) Dem menschlichen gewebefaktor ähnliche dns-segmente, polypeptide und antikörper
DE68926303D1 (de) Peptide und antikörper, die die integrin-ligandbindung inhibieren
ATE262038T1 (de) Br96 mutantantikörper die mit menschlichen karzinomen reagieren
IL69469A (en) Polypeptide having human h1-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
DE851876T1 (de) Peptide des antisekretonischen faktors, welches krankhafte permeabilitätsanderungen reguliert
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
NO980122L (no) Emaljematriksrelatert polypeptid
ATE77834T1 (de) Human-parathyroidhormon (human-pth) produzierende hybridvektor.
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
ATE163939T1 (de) Peptide und antikörper zur behandlung von rheumatoider arthritis.
IE830197L (en) Preparation of porcine relaxin
PT1847607E (pt) Anticorpos contra a proteína p51
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
ATE237345T1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
Hundle Synthesis and use of a membrane-impermeable guanidinating reagent, 2-S-(carbon-14) thiuronium ethane sulfonate for the labeling of light-harvesting proteins in Rhodobacter sphaeroides.
ATE310083T1 (de) Deprenyl induziertes protein
NZ228194A (en) Monoclonal antibodies which bind to the n-terminal peptide sequence of the betasubunit of human haemoglobiin

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees